Related Experiment Videos
Individualized risk for statin-induced myopathy: current knowledge, emerging challenges and potential solutions
QiPing Feng1, Russell A Wilke, Tesfaye M Baye
1Department of Medicine, Vanderbilt University Medical Center, Oates Institute for Experimental Therapeutics, Nashville, TN, USA.
Pharmacogenomics
|April 3, 2012
Summary
Statin-induced myopathy risk is influenced by genetic and non-genetic factors. Understanding these determinants, including SLCO1B1 and RYR2 gene variants and racial differences, is crucial for personalized statin therapy.
Area of Science:
- Pharmacogenomics
- Clinical Pharmacology
- Genetics
Background:
- Skeletal muscle toxicity is a significant adverse effect of statin medications.
- Genetic and non-genetic factors contribute to the risk of statin-induced myopathy.
Purpose of the Study:
- To review current knowledge on the genetic and non-genetic determinants of statin-induced myopathy.
- To highlight key genes and factors influencing myopathy risk.
Main Methods:
- Review of candidate gene association studies and genome-wide association studies (GWAS).
- Analysis of pharmacokinetic (PK) and pharmacodynamic targets.
- Consideration of environmental factors and race as covariates.
Main Results:
- SLCO1B1 is a strong predictor of myopathy risk based on GWAS.
- RYR2 identified as a pharmacodynamic candidate gene.
- Race is a critical factor, with influence not fully explained by known variants.
Conclusions:
- Future research should focus on deep resequencing for rare variants and computational approaches for gene-gene and gene-environment interactions.
- Admixture analyses are essential for a comprehensive understanding of statin-induced myopathy, considering the role of race.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
01:14Myocarditis III: Medical Management
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
01:22Myocarditis IV: Nursing Management
Myocarditis is an inflammatory condition of the myocardium requiring meticulous nursing management for optimal patient outcomes. Effective management begins with a thorough assessment of the patient's medical history, paying close attention to past infections, autoimmune disorders, travel history, and exposure to toxins or drugs. Recent viral infections and systemic diseases are particularly relevant due to their potential role in triggering myocarditis.Physical Examination and MonitoringThe...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:22Myasthenia Gravis ll: Pathophysiology
The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...